Wall Street achieved record highs as healthcare stocks saw notable movements.

Follow live text commentary, score updates and match stats from AIK vs IFK Göteborg in the Allsvenskan ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss ...

"Hey Meta send a message to ChatGPT" Mai: A Hacky Messenger browser extension & pseudo API for the Meta Glasses :eyeglasses: - dcrebbin/meta-glasses-api ...

Novo Nordisk (NVO) said it expanded patient access to Wegovy through a new collaboration with WeightWatchers, beginning July 1. WeightWatchers will work with CenterWell Pharmacy as the dispensing ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.

The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that advance health and sustainability through cooperation ...

Tentatively, although not required for the de novo differentiation of naive CD4 cells towards Th-17 cells, IL-23 seems to be important for further programming, survival and expansion of Th-17 ...

Several in vivo studies in mice suggest that ‘the immunological axis' IL-23 IL-17 plays an important role in pulmonary host defense. Taking into consideration the role of IL-23 in the ...

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to expand access to its blockbuster weight loss drug Wegovy (semaglutide). The ...